塔尔苏斯制药 TARS
$68.60 +$1.08 (+1.60%)
休市 · Nov 8, 5:10 am ET · 最新盘后价 $70.00 +2.04%
开盘$67.78
昨收$67.52
当日区间$66.53 – $69.04
成交量1.09M
市值$3.38B
市盈率（TTM）–
股息率–
TARS 相关新闻
匹配 Tarsus Pharmaceuticals 或代码 TARS 的头条新闻，按最新排序。
- Jefferies Initiates Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Announces Target Price $105
- Goldman Sachs Upgrades Tarsus Pharmaceuticals(TARS.US) to Buy Rating, Raises Target Price to $116 正面
- Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $110 正面
- LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $104
- LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $104 正面
- Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100 正面
- H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88
- Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $98
- William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
- Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100
- Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100 正面
- A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $88 to $100
- Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Prime Medicine, Inc. (PRME) and Ascendis Pharma (ASND)
- Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $98 负面
- Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $89 负面
暂无评论——快来第一个聊聊 TARS。
登录后参与讨论。